retatrutide type 2 diabetes phase 2 trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA Retatrutide as a Novel Treatment

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way

Product Type: Peptide Product

State employee plans and federal employee plans often have better coverage than individual market plans

3739 While it is encouraging that the weight loss achieved with GLP-1/GIPGLP-1 receptor agonists approaches levels typically seen after bariatric procedures such as gastric bypass or sleeve gastrectomy, the rapid regain of a significant portion of the lost weight after treatment discontinuation, accompanied by a reduction in lean body mass, raises new clinical concerns

The tesamorelin + ipamorelin stack remains the safest option for both sexes, as ipamorelins selectivity avoids prolactin elevation that non-selective GHRPs like GHRP-2 or GHRP-6 can trigger